HOMEIndia News
| India’s Jubilant Life Sciences signs licensing deal for remdesivir drug | Writer | Admin | |||
|---|---|---|---|---|---|
India’s Jubilant Life Sciences Ltd said on Tuesday it had signed a
non-exclusive licensing agreement for selling Gilead Sciences Inc’s
experimental Covid-19 treatment remdesivir in 127 countries, including India.
The drug earlier
this month received the US Food and Drug Administration’s emergency use authorization
to treat Covid-19 patients.
Jubilant also gets
the rights to manufacture the drug and scale up production in nearly all
low-income and middle-income countries, as well as some high-income nations.
|
| No | Subject | Writer | Date |
|---|---|---|---|
| 319 | Electric two-wheeler sales contract 5% in 2020, industry to ask for changes in E… | Admin | 21-01-07 |
| 318 | Cabinet approves signing of Memorandum of Cooperation between India and Japan on… | Admin | 21-01-07 |
| 317 | Chabahar Port a game changer, achieves record single loading of cargo: Union Min… | Admin | 20-07-02 |
| 316 | India relaxes customs checks for Chinese-origin goods of US, South Korean compan… | Admin | 20-07-02 |
| 315 | Murugappa Group eyes CG Power, ready to invest Rs 750 crore | Admin | 20-07-02 |
| 314 | Export sops likely to continue till March 2021 | Admin | 20-05-18 |
| 313 | Dishwashers, refrigerators, trimmers, large screen TVs becoming preferred applia… | Admin | 20-05-18 |
| 312 | Philips to invest Rs 300 crore in India manufacturing, R&D | Admin | 20-05-18 |
| 311 | India's Rs 20 lakh crore Covid relief package one among the largest in the world | Admin | 20-05-13 |
| 310 | India’s Jubilant Life Sciences signs licensing deal for remdesivir drug | Admin | 20-05-13 |